Knowledge Gaps in the Treatment of Atopic Dermatitis
Main Article Content
Abstract
Atopic dermatitis is a complex chronic inflammatory skin disorder with a rising global prevalence, affecting 2.6% of the population worldwide. Its multifactorial nature, influenced by genetic, environmental, and immunological factors, challenges effective treatment and management. This article highlights key knowledge gaps in atopic dermatitis treatment, including genetic predispositions, diagnostic dilemmas, pruritus management, and psychosocial impacts. It emphasizes the need for a personalized approach to atopic dermatitis care, leveraging advancements in genetic research, metabolomics, and biomarkers to enhance drug discovery and improve disease outcomes. Despite various therapeutic options, there remains an unmet need for treatments that effectively address atopic dermatitis’ physical, psychological, and socioeconomic burdens. The role of psychosocial factors, treatment adherence, and the economic impact of atopic dermatitis are also explored. Current therapeutic approaches remain inadequate, underscoring the need for continued research into novel targeted therapies and improved patient care strategies.
Article Details
How to Cite
CRITON, V. J. Sebastian; BRAHMAKULAM, Regina Jacob.
Knowledge Gaps in the Treatment of Atopic Dermatitis.
Medical Research Archives, [S.l.], v. 12, n. 11, nov. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6098>. Date accessed: 12 dec. 2024.
doi: https://doi.org/10.18103/mra.v12i11.6098.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3-16. doi:10.1111/all.12270
2. Puerta Durango K, Chiesa Fuxench ZC. Global Burden of Atopic Dermatitis: Examining Disease Prevalence Across Pediatric and Adult Populations World-Wide. Dermatol Clin. 2024;42(4):519-525. doi:10.1016/j.det.2024.05.004
3. Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022;12(12):2653-2668. doi:10.1007/s13555-022-00819-6
4. Silverberg JI, Nelson DB, Yosipovitch G. Addressing treatment challenges in atopic dermatitis with novel topical therapies. J Dermatolog Treat. 2016;27(6):568-576. doi:10.1080/09546634.2016.1174765
5. T, Ferreira EO, Gonçalo M, Mendes-Bastos P, Selores M, Filipe P. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606-613. doi:10.20344/amp.11963
6. Marenholz I, Arnau-Soler A, Rosillo-Salazar OD, Lee YA. New insights from genetic studies of eczema. Med Genet. 2023;35(1):33-45. doi:10.1515/medgen-2023-2010
7. MedlinePlus. GWAS Studies. National Library of Medicine website. https://medlineplus.gov/genetics/understanding/genomicresearch/gwastudies/. Accessed August 25, 2024.
8. Løset M, Brown SJ, Saunes M, Hveem K. Genetics of Atopic Dermatitis: From DNA Sequence to Clinical Relevance. Dermatology. 2019;235(5):355-364. doi:10.1159/000500402
9. Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet. 2014;59(1):5-15. doi:10.1038/jhg.2013.114
10. Brown SJ. What have we learned from GWAS for atopic dermatitis? J Invest Dermatol. 2021;141(1):19-22. doi:10.1016/j.jid.2020.05.100
11. Bastarache L, Denny JC, Roden DM. Phenome-Wide Association Studies. JAMA. 2022;327(1):75-76. doi:10.1001/jama.2021.20356
12. Braun JM, Kalloo G, Kingsley SL, Li N. Using phenome-wide association studies to examine the effect of environmental exposures on human health. Environ Int. 2019;130:104877. doi:10.1016/j.envint.2019.05.071
13. Zhang L, Zeng Y, Sun J. Progress of metabolomics in atopic dermatitis: a systematic review. J Dtsch Dermatol Ges. 2023;21(3):229-236. doi:10.1111/ddg.14960
14. Mucha S, Baurecht H, Novak N, et al. Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression. J Allergy Clin Immunol. 2020;145(4):1208-1218. doi:10.1016/j.jaci.2019.10.030
15. Melku M, Asrie F, Shiferaw E, et al. Knowledge, attitude, and practice regarding blood donation among graduating undergraduate health science students at the University of Gondar, Northwest Ethiopia. Ethiop J Health Sci. 2018;28(5):571-582. doi:10.4314/ejhs.v28i5.8
16. Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158(4):754-765. doi:10.1111/j.1365-2133.2007.08412.x
17. Thyssen JP, Andersen Y, Halling AS, Williams HC, Egeberg A. Strengths and limitations of the United Kingdom Working Party criteria for atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2020;34(8):1764-1772. doi:10.1111/jdv.16364
18. Ben-Gashir MA, Hay RJ. Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. Br J Dermatol. 2002;147(5):920-925. doi:10.1046/j.1365-2133.2002.04965.x
19. Amon U, Memmel U, Stoll R, Amon S. Comparison of severity scoring of atopic dermatitis values and serum levels of eosinophil cationic protein and mast cell tryptase for routine evaluation of atopic dermatitis. Acta Derm Venereol. 2000;80(4):284-286. doi:10.1080/000155500750012180
20. Dhar S, Malakar R, Chattopadhyay S, Dhar S, Banerjee R, Ghosh A. Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum IgE levels. Indian J Dermatol Venereol Leprol. 2005;71(4):246-249. doi:10.4103/0378-6323.16615
21. Despite significant research efforts and the investigation of numerous biomarkers, including nitric oxide synthase 2/inducible nitric oxide synthase (NOS2/iNOS), matrix metalloproteinases (MMPs), human beta-defensin 2 (hBD-2), IL-36α, IL-36γ, CCL26, and CXCL9, the clinical application of these markers remains uncertain. This is largely due to limitations such as small sample sizes and the lack of standardized detection methods. As a result, their routine use in clinical practice has yet to be established.
22. Yu L, Li L. Potential biomarkers of atopic dermatitis. Front Med (Lausanne). 2022;9:1028694. Published 2022 Nov 17. doi:10.3389/fmed.2022.1028694
23. Libon, F., Caron, J. & Nikkels, A.F. Biomarkers in Atopic Dermatitis. Dermatol Ther (Heidelb) 14, 1729–1738 (2024). https://doi.org/10.1007/s13555-024-01193-1
24. Dawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol. 2009;160(3):642-644. doi:10.1111/j.1365-2133.2008.08941.x-1
25. Silverberg JI. Practice Gaps in Pruritus. Dermatol Clin. 2016;34(3):257-261. doi:10.1016/j.det.2016.02.008-8
26. Murray CS, Rees JL. Are subjective accounts of itch to be relied on? The lack of relation between visual analogue itch scores and actigraphic measures of scratch. *Acta Derm Venereol.* 2011;91(1):18-23.-9
27. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol. 2009;89(4):339-350. doi:10.2340/00015555-0662-10
28. Bathe A, Weisshaar E, Matterne U. Chronic pruritus--more than a symptom: a qualitative investigation into patients' subjective illness perceptions. J Adv Nurs. 2013;69(2):316-326. doi:10.1111/j.1365-2648.2012.06009.x-11
29. Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol. 2018;19(3):319-332. doi:10.1007/s40257-017-0335-4-5
30. Choi EH, Brown BE, Crumrine D, et al. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol. 2005;124(3):587-595. doi:10.1111/j.0022-202X.2005.23589.x-4
31. Jafferany M, Davari ME. Itch and psyche: psychiatric aspects of pruritus. Int J Dermatol. 2019;58(1):3-23. doi:10.1111/ijd.14081-12
32. Schut C, Mollanazar NK, Kupfer J, Gieler U, Yosipovitch G. Psychological interventions in the treatment of chronic itch. Acta Derm Venereol. 2016;96(2):157-161. doi:10.2340/00015555-2177-2
33. Primary Care Dermatology Society. Habit reversal therapy. Available at: https://www.pcds.org.uk/files/gallery/Habit-reversal-therapy.pdf. Accessed August 25, 2024.-3
34. Lewis KE, Holdren MS, Maurer MF, et al. Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody. J Eur Acad Dermatol Venereol. 2017;31(1):142-150. doi:10.1111/jdv.13820-6
35. Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826-835. doi:10.1056/NEJMoa1606490-7
36. Weisshaar E, Apfelbacher C, Jäger G, et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol. 2006;155(5):957-964. doi:10.1111/j.1365-2133.2006.07430.x-17
37. Navarro-Triviño FJ. Pruritus in Dermatology: Part 2 - Diseases and Their Treatment. Prurito en dermatología. Enfermedades y su tratamiento. Parte 2. Actas Dermosifiliogr. 2023;114(7):613-626. doi:10.1016/j.ad.2023.03.004-14
38. Roh YS, Choi J, Sutaria N, Kwatra SG. Itch: Epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol. 2022;86(1):1-14. doi:10.1016/j.jaad.2021.07.076-13
39. Moses S. Pruritus. *American Family Physician.* 2003 Sep 15;68(6):1135-42.-15
40. Reszke R, Szepietowski JC. Itch and Psyche: Bilateral Associations. Acta Derm Venereol. 2020;100(2):adv00026. doi:10.2340/00015555-3346-10
41. Paus R, Schmelz M, Bíró T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest. 2006;116(5):1174-1186. doi:10.1172/JCI28553-11
42. Greaves MW, Khalifa N. Itch: more than skin deep. Int Arch Allergy Immunol. 2004;135(2):166-172. doi:10.1159/000080898-12
43. Lin TK, Zhong L, Santiago JL. Association between Stress and the HPA Axis in the Atopic Dermatitis. Int J Mol Sci. 2017;18(10):2131. Published 2017 Oct 12. doi:10.3390/ijms18102131-14
44. Golpanian RS, Kim HS, Yosipovitch G. Effects of Stress on Itch. Clin Ther. 2020;42(5):745-756. doi:10.1016/j.clinthera.2020.01.025-15
45. Lin TK, Zhong L, Santiago JL. Association between Stress and the HPA Axis in the Atopic Dermatitis. Int J Mol Sci. 2017;18(10):2131. Published 2017 Oct 12. doi:10.3390/ijms18102131-16
46. Misery L, Seneschal J, Corgibet F, et al. Impact of atopic dermatitis on patients and their partners. Acta Derm Venereol. 2023;103. doi:10.2340/actadv.v103.5285-5
47. Misery L, Finlay AY, Martin N, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology. 2007;215(2):123-129. doi:10.1159/000104263-6
48. Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on families: A review. Pediatr Dermatol. 2019;36(1):66-71. doi:10.1111/pde.13727-3
49. Pärna E, Aluoja A, Kingo K. Quality of life and emotional state in chronic skin disease. Acta Derm Venereol. 2015;95(3):312-316. doi:10.2340/00015555-1920-8
50. Montgomery K, Thompson AR. The potential role of mindfulness in psychosocial support for dermatology patients. Clin Dermatol. 2018;36(6):743-747. doi:10.1016/j.clindermatol.2018.08.010-7
51. Patel A, Jafferany M. Multidisciplinary and Holistic Models of Care for Patients With Dermatologic Disease and Psychosocial Comorbidity: A Systematic Review. JAMA Dermatol. 2020;156(6):686-694. doi:10.1001/jamadermatol.2020.0394-9
52. Michelle LW, Yan L, Soon-Leong AT, Liang TH. Effectiveness of a multidisciplinary itch clinic in the management of chronic pruritus [published correction appears in Indian J Dermatol. 2015 May-Jun;60(3):319. doi: 10.4103/0019-5154.156412]. Indian J Dermatol. 2015;60(2):218. doi:10.4103/0019-5154.152598-13
53. Ezzedine K, Shourick J, Merhand S, Sampogna F, Taïeb C. Impact of atopic dermatitis in adolescents and their parents: A French study. Acta Derm Venereol. 2020;100(17).doi:10.2340/00015555-3653-4
54. Talamonti M, Galluzzo M, Silvaggio D, Lombardo P, Tartaglia C, Bianchi L. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med. 2021;10(6):1298. doi:10.3390/jcm10061298-1
55. Kobusiewicz AK, Tarkowski B, Kaszuba A, Lesiak A, Narbutt J, Zalewska-Janowska A. The relationship between atopic dermatitis and atopic itch in children and the psychosocial functioning of their mothers: A cross-sectional study. Front Med (Lausanne). 2023;10:1066495. doi:10.3389/fmed.2023.1066495-2
56. Shin JO, Kim K, Kim HS, et al. Geographic differences in atopic dermatitis risk between urban and rural area: A systematic review and meta-analysis. J Dtsch Dermatol Ges. 2023;21(9):973-982. doi:10.1111/ddg.15135
57. Bilgic A, Bozca BC, Subası GY, et al. Standard Patch Test Results and Clinical Relevance: A Cross-Sectional Study of 10-year Retrospective Experience. Indian J Dermatol. 2022;67(3):258-264. doi:10.4103/ijd.ijd_965_21. PMID: 36386088; PMCID: PMC9644757.
58. Lefevre MA, Nosbaum A, Mosnier A, et al. Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis. J Am Acad Dermatol. 2024;90(5):953-962. doi:10.1016/j.jaad.2023.11.066
59. World Health Organization (WHO). Immunizing the public against misinformation. Available at: https://www.who.int/news-room/feature-stories/detail/immunizing-the-public-againstmisinformation. Accessed August 20, 2024.
60. O'Connor C, Murphy M. Scratching the surface: a review of online misinformation and conspiracy theories in atopic dermatitis. Clin Exp Dermatol. 2021;46(8):1545-1547. doi:10.1111/ced.14679
61. Mueller S, Hongler V, Jungo P, et al. Fiction, falsehoods, and few facts: cross-sectional study on the content-related quality of atopic eczema-related videos on YouTube. J Med Internet Res. 2020;22(4). doi:10.2196/15599
62. Johnston GA, Bilbao RM, Graham-Brown RA. The use of dietary manipulation by parents of children with atopic dermatitis. Br J Dermatol. 2004;150(6):1186-1189. doi:10.1111/j.1365-2133.2004.05888.x
63. Webber SA, Graham-Brown RA, Hutchinson PE, Burns DA. Dietary manipulation in childhood atopic dermatitis. Br J Dermatol. 1989;121(1):91-98. doi:10.1111/j.1365-2133.1989.tb01404.x
64. Hon KL, Nip SY, Cheung KL. A tragic case of atopic eczema: malnutrition and infections despite multivitamins and supplements. Iran J Allergy Asthma Immunol. 2012;11(3):267-270. PMID:22947914
65. Mori F, Serranti D, Barni S, et al. A kwashiorkor case due to the use of an exclusive rice milk diet to treat atopic dermatitis. Nutr J. 2015;14:83. doi:10.1186/s12937-015-0071-7
66. Tierney EP, Sage RJ, Shwayder T. Kwashiorkor from a severe dietary restriction in an 8-month infant in suburban Detroit, Michigan: case report and review of the literature. Int J Dermatol. 2010;49(5):500-506. doi:10.1111/j.1365-4632.2010.04253.x
67. Patel NU, D’Ambra V, Feldman SR. Increasing Adherence with Topical Agents for Atopic Dermatitis. Am J Clin Dermatol. 2017;18:323-332. doi:10.1007/s40257-017-0261-5.
68. Smith SD, Farrugia LL, Harris V, et al. Evaluation of the Influence of Family and Friends, and the Internet on Patient Perceptions of Long-Term Topical Corticosteroid Use. J Dermatolog Treat. 2017;28(7):642-646. doi:10.1080/09546634.2017.1306017. PMID: 28349719.
69. Dufresne H, Bataille P, Bellon N, et al. Risk Factors for Corticophobia in Atopic Dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12). doi:10.1111/jdv.16739. PMID: 32526095.
70. Kojima R, Fujiwara T, Matsuda A, et al. Factors Associated with Steroid Phobia in Caregivers of Children with Atopic Dermatitis. Pediatr Dermatol. 2013;30(1):29-35. doi:10.1111/j.1525-1470.2012.01808.x. PMID: 22747965.
71. Mueller SM, Tomaschett D, Vogt DR, et al. Topical Corticosteroid Concerns from the Clinicians' Perspective. J Dermatolog Treat. 2017;28(5):464-468. doi:10.1080/09546634.2016.1255307. PMID: 27807999.
72. Choi E, Tan KW, Tang F, Tan C, Chandran NS. Efficacy of Targeted Education in Reducing Topical Steroid Phobia: A Randomized Clinical Trial. J Am Acad Dermatol. 2020;83(6):1681-1687. doi:10.1016/j.jaad.2020.02.079. PMID: 32171815.
73. Smith SD, Stephens AM, Werren JC, Fischer GO. Treatment Failure in Atopic Dermatitis as a Result of Parental Health Belief. Med J Aust. 2013;199(7):467-469. doi:10.5694/mja12.10802. PMID: 24099206.
74. Contento M, Cline A, Russo M. Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions. Am J Clin Dermatol. 2021;22(6):837-851. doi:10.1007/s40257-021-00623-6. PMID: 34287768.
75. Flohr C. How We Treat Atopic Dermatitis Now and How That Will Change Over the Next 5 Years. Br J Dermatol. 2023;188(6):718-725. doi:10.1093/bjd/ljac116. PMID: 36715500.
76. Wilkes SR, Nankervis H, Tavernier E, Maruani A, Williams HC. How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema? J Invest Dermatol. 2016;136(10):1944-1949. doi:10.1016/j.jid.2016.05.104. PMID: 27265005.
77. The Treatment of Severe Atopic Eczema in Children Taskforce. Available at: https://treat-trial.org.uk. Accessed August 25, 2024.
78. Beacon Trial – Best Systemic Treatments for Adults with Atopic Eczema Over the Long Term. Available at: https://beacontrial.org. Accessed August 25, 2024.
79. Cochrane Training. Available at: https://training.cochrane.org/handbook/current/chapter-11. Accessed August 25, 2024.
80. Patel N, Sil A. Dermatology and Randomized Control Trials. Indian Dermatol Online J. 2021;12(3):400-407. doi:10.4103/idoj.IDOJ_715_20. PMID: 34211905; PMCID: PMC8202471.
81. Spelsberg A, Prugger C, Doshi P, et al. Contribution of Industry Funded Post-Marketing Studies to Drug Safety: Survey of Notifications Submitted to Regulatory Agencies. BMJ. 2017;356. doi:10.1136/bmj.j337. PMID: 28174182; PMCID: PMC5477378.
82. Vermeulen FM, Gerbens LAA, Bosma AL, et al. TREatment of ATopic Eczema (TREAT) Registry Taskforce: Consensus on How and When to Measure the Core Dataset for Atopic Eczema Treatment Research Registries. Br J Dermatol. 2019;181(3):492-504. doi:10.1111/bjd.17715. PMID: 30719709; PMCID: PMC6771812.
83. Home for Eczema. Available at: https://www.homeforeczema.org/about/about.aspx. Accessed August 25, 2024.
84. Bieber T. Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease. Nat Rev Drug Discov. 2022;21(1):21-40. doi:10.1038/s41573-021-00266-6. PMID: 34417579; PMCID: PMC8377708.
85. Augustin M, Langenbruch A, Blome C, et al. Characterizing Treatment-Related Patient Needs in Atopic Eczema: Insights for Personalized Goal Orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142-152. doi:10.1111/jdv.15919. Erratum in: J Eur Acad Dermatol Venereol. 2020;34(5):1118. doi:10.1111/jdv.16351. PMID: 31465587.
86. BIOMAP - Biomarkers in Atopic Dermatitis and Psoriasis. Available at: https://www.biomap-imi.eu/overview. Accessed August 25, 2024.
87. Eczema Therapies. Eczema Therapies website. https://eczematherapies.com/. Updated July 17, 2024. Accessed September 26, 2024.
88. Li W, Yosipovitch G. The role of the microbiome and microbiome-derived metabolites in atopic dermatitis and non-histaminergic itch. Am J Clin Dermatol. 2020;21:44-50. doi:10.1007/s40257-019-00495-z.
89. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-859. doi:10.1101/gr.131029.111.
90. De Pessemier B, Grine L, Debaere M, Maes A, Paetzold B, Callewaert C. Gut–Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. Microorganisms. 2021; 9(2):353. https://doi.org/10.3390/microorganisms9020353
91. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-859. doi:10.1101/gr.131029.111
92. Song H, Yoo Y, Hwang J, Na YC, Kim HS. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol. 2016;137(3):852-860. doi:10.1016/j.jaci.2015.08.021
93. Lee E, Lee SY, Kang MJ, Kim K, Won S, Kim BJ, Choi KY, Kim BS, Cho HJ, Kim Y, et al. Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammation. Ann Allergy Asthma Immunol. 2016;117(1):91-92.
94. Kim NY, Ji GE. Effects of probiotics on the prevention of atopic dermatitis. Korean J Pediatr. 2012;55(6):193-201. doi:10.3345/kjp.2012.55.6.193
95. Zhao H, Ma X, Song J, et al. From gut to skin: exploring the potential of natural products targeting microorganisms for atopic dermatitis treatment. Food Funct. 2023;14(17):7825-7852. Published 2023 Aug 29. doi:10.1039/d3fo02455e
96. Anania C, Brindisi G, Martinelli I, et al. Probiotics Function in Preventing Atopic Dermatitis in Children. International Journal of Molecular Sciences. 2022;23(10):5409-5409
97. Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38(2):340-353. doi:10.1111/jdv.19500
98. Augustin M, Misery L, von Kobyletzski L, et al. Systematic literature review assessing the overall costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2022;36(12):2316-2324. doi:10.1111/jdv.18481
99. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. doi:10.1016/j.jid.2016.07.012
100. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. doi:10.1016/j.jid.2016.07.012
101. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol. 2002;46(3):361-370. doi:10.1067/mjd.2002.120528
102. Drucker AM, Wang AR, Qureshi AA. Research gaps in quality of life and economic burden of atopic dermatitis: the National Eczema Association burden of disease audit. JAMA Dermatol. 2016;152(8):873-874. doi:10.1001/jamadermatol.2016.1978
103. Ismail N, Bray N. Atopic dermatitis: economic burden and strategies for high-quality care. Br J Dermatol. 2020;182(5):1087-1088. doi:10.1111/bjd.18636
2. Puerta Durango K, Chiesa Fuxench ZC. Global Burden of Atopic Dermatitis: Examining Disease Prevalence Across Pediatric and Adult Populations World-Wide. Dermatol Clin. 2024;42(4):519-525. doi:10.1016/j.det.2024.05.004
3. Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022;12(12):2653-2668. doi:10.1007/s13555-022-00819-6
4. Silverberg JI, Nelson DB, Yosipovitch G. Addressing treatment challenges in atopic dermatitis with novel topical therapies. J Dermatolog Treat. 2016;27(6):568-576. doi:10.1080/09546634.2016.1174765
5. T, Ferreira EO, Gonçalo M, Mendes-Bastos P, Selores M, Filipe P. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606-613. doi:10.20344/amp.11963
6. Marenholz I, Arnau-Soler A, Rosillo-Salazar OD, Lee YA. New insights from genetic studies of eczema. Med Genet. 2023;35(1):33-45. doi:10.1515/medgen-2023-2010
7. MedlinePlus. GWAS Studies. National Library of Medicine website. https://medlineplus.gov/genetics/understanding/genomicresearch/gwastudies/. Accessed August 25, 2024.
8. Løset M, Brown SJ, Saunes M, Hveem K. Genetics of Atopic Dermatitis: From DNA Sequence to Clinical Relevance. Dermatology. 2019;235(5):355-364. doi:10.1159/000500402
9. Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet. 2014;59(1):5-15. doi:10.1038/jhg.2013.114
10. Brown SJ. What have we learned from GWAS for atopic dermatitis? J Invest Dermatol. 2021;141(1):19-22. doi:10.1016/j.jid.2020.05.100
11. Bastarache L, Denny JC, Roden DM. Phenome-Wide Association Studies. JAMA. 2022;327(1):75-76. doi:10.1001/jama.2021.20356
12. Braun JM, Kalloo G, Kingsley SL, Li N. Using phenome-wide association studies to examine the effect of environmental exposures on human health. Environ Int. 2019;130:104877. doi:10.1016/j.envint.2019.05.071
13. Zhang L, Zeng Y, Sun J. Progress of metabolomics in atopic dermatitis: a systematic review. J Dtsch Dermatol Ges. 2023;21(3):229-236. doi:10.1111/ddg.14960
14. Mucha S, Baurecht H, Novak N, et al. Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression. J Allergy Clin Immunol. 2020;145(4):1208-1218. doi:10.1016/j.jaci.2019.10.030
15. Melku M, Asrie F, Shiferaw E, et al. Knowledge, attitude, and practice regarding blood donation among graduating undergraduate health science students at the University of Gondar, Northwest Ethiopia. Ethiop J Health Sci. 2018;28(5):571-582. doi:10.4314/ejhs.v28i5.8
16. Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158(4):754-765. doi:10.1111/j.1365-2133.2007.08412.x
17. Thyssen JP, Andersen Y, Halling AS, Williams HC, Egeberg A. Strengths and limitations of the United Kingdom Working Party criteria for atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2020;34(8):1764-1772. doi:10.1111/jdv.16364
18. Ben-Gashir MA, Hay RJ. Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. Br J Dermatol. 2002;147(5):920-925. doi:10.1046/j.1365-2133.2002.04965.x
19. Amon U, Memmel U, Stoll R, Amon S. Comparison of severity scoring of atopic dermatitis values and serum levels of eosinophil cationic protein and mast cell tryptase for routine evaluation of atopic dermatitis. Acta Derm Venereol. 2000;80(4):284-286. doi:10.1080/000155500750012180
20. Dhar S, Malakar R, Chattopadhyay S, Dhar S, Banerjee R, Ghosh A. Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum IgE levels. Indian J Dermatol Venereol Leprol. 2005;71(4):246-249. doi:10.4103/0378-6323.16615
21. Despite significant research efforts and the investigation of numerous biomarkers, including nitric oxide synthase 2/inducible nitric oxide synthase (NOS2/iNOS), matrix metalloproteinases (MMPs), human beta-defensin 2 (hBD-2), IL-36α, IL-36γ, CCL26, and CXCL9, the clinical application of these markers remains uncertain. This is largely due to limitations such as small sample sizes and the lack of standardized detection methods. As a result, their routine use in clinical practice has yet to be established.
22. Yu L, Li L. Potential biomarkers of atopic dermatitis. Front Med (Lausanne). 2022;9:1028694. Published 2022 Nov 17. doi:10.3389/fmed.2022.1028694
23. Libon, F., Caron, J. & Nikkels, A.F. Biomarkers in Atopic Dermatitis. Dermatol Ther (Heidelb) 14, 1729–1738 (2024). https://doi.org/10.1007/s13555-024-01193-1
24. Dawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol. 2009;160(3):642-644. doi:10.1111/j.1365-2133.2008.08941.x-1
25. Silverberg JI. Practice Gaps in Pruritus. Dermatol Clin. 2016;34(3):257-261. doi:10.1016/j.det.2016.02.008-8
26. Murray CS, Rees JL. Are subjective accounts of itch to be relied on? The lack of relation between visual analogue itch scores and actigraphic measures of scratch. *Acta Derm Venereol.* 2011;91(1):18-23.-9
27. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol. 2009;89(4):339-350. doi:10.2340/00015555-0662-10
28. Bathe A, Weisshaar E, Matterne U. Chronic pruritus--more than a symptom: a qualitative investigation into patients' subjective illness perceptions. J Adv Nurs. 2013;69(2):316-326. doi:10.1111/j.1365-2648.2012.06009.x-11
29. Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol. 2018;19(3):319-332. doi:10.1007/s40257-017-0335-4-5
30. Choi EH, Brown BE, Crumrine D, et al. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol. 2005;124(3):587-595. doi:10.1111/j.0022-202X.2005.23589.x-4
31. Jafferany M, Davari ME. Itch and psyche: psychiatric aspects of pruritus. Int J Dermatol. 2019;58(1):3-23. doi:10.1111/ijd.14081-12
32. Schut C, Mollanazar NK, Kupfer J, Gieler U, Yosipovitch G. Psychological interventions in the treatment of chronic itch. Acta Derm Venereol. 2016;96(2):157-161. doi:10.2340/00015555-2177-2
33. Primary Care Dermatology Society. Habit reversal therapy. Available at: https://www.pcds.org.uk/files/gallery/Habit-reversal-therapy.pdf. Accessed August 25, 2024.-3
34. Lewis KE, Holdren MS, Maurer MF, et al. Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody. J Eur Acad Dermatol Venereol. 2017;31(1):142-150. doi:10.1111/jdv.13820-6
35. Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826-835. doi:10.1056/NEJMoa1606490-7
36. Weisshaar E, Apfelbacher C, Jäger G, et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol. 2006;155(5):957-964. doi:10.1111/j.1365-2133.2006.07430.x-17
37. Navarro-Triviño FJ. Pruritus in Dermatology: Part 2 - Diseases and Their Treatment. Prurito en dermatología. Enfermedades y su tratamiento. Parte 2. Actas Dermosifiliogr. 2023;114(7):613-626. doi:10.1016/j.ad.2023.03.004-14
38. Roh YS, Choi J, Sutaria N, Kwatra SG. Itch: Epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol. 2022;86(1):1-14. doi:10.1016/j.jaad.2021.07.076-13
39. Moses S. Pruritus. *American Family Physician.* 2003 Sep 15;68(6):1135-42.-15
40. Reszke R, Szepietowski JC. Itch and Psyche: Bilateral Associations. Acta Derm Venereol. 2020;100(2):adv00026. doi:10.2340/00015555-3346-10
41. Paus R, Schmelz M, Bíró T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest. 2006;116(5):1174-1186. doi:10.1172/JCI28553-11
42. Greaves MW, Khalifa N. Itch: more than skin deep. Int Arch Allergy Immunol. 2004;135(2):166-172. doi:10.1159/000080898-12
43. Lin TK, Zhong L, Santiago JL. Association between Stress and the HPA Axis in the Atopic Dermatitis. Int J Mol Sci. 2017;18(10):2131. Published 2017 Oct 12. doi:10.3390/ijms18102131-14
44. Golpanian RS, Kim HS, Yosipovitch G. Effects of Stress on Itch. Clin Ther. 2020;42(5):745-756. doi:10.1016/j.clinthera.2020.01.025-15
45. Lin TK, Zhong L, Santiago JL. Association between Stress and the HPA Axis in the Atopic Dermatitis. Int J Mol Sci. 2017;18(10):2131. Published 2017 Oct 12. doi:10.3390/ijms18102131-16
46. Misery L, Seneschal J, Corgibet F, et al. Impact of atopic dermatitis on patients and their partners. Acta Derm Venereol. 2023;103. doi:10.2340/actadv.v103.5285-5
47. Misery L, Finlay AY, Martin N, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology. 2007;215(2):123-129. doi:10.1159/000104263-6
48. Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on families: A review. Pediatr Dermatol. 2019;36(1):66-71. doi:10.1111/pde.13727-3
49. Pärna E, Aluoja A, Kingo K. Quality of life and emotional state in chronic skin disease. Acta Derm Venereol. 2015;95(3):312-316. doi:10.2340/00015555-1920-8
50. Montgomery K, Thompson AR. The potential role of mindfulness in psychosocial support for dermatology patients. Clin Dermatol. 2018;36(6):743-747. doi:10.1016/j.clindermatol.2018.08.010-7
51. Patel A, Jafferany M. Multidisciplinary and Holistic Models of Care for Patients With Dermatologic Disease and Psychosocial Comorbidity: A Systematic Review. JAMA Dermatol. 2020;156(6):686-694. doi:10.1001/jamadermatol.2020.0394-9
52. Michelle LW, Yan L, Soon-Leong AT, Liang TH. Effectiveness of a multidisciplinary itch clinic in the management of chronic pruritus [published correction appears in Indian J Dermatol. 2015 May-Jun;60(3):319. doi: 10.4103/0019-5154.156412]. Indian J Dermatol. 2015;60(2):218. doi:10.4103/0019-5154.152598-13
53. Ezzedine K, Shourick J, Merhand S, Sampogna F, Taïeb C. Impact of atopic dermatitis in adolescents and their parents: A French study. Acta Derm Venereol. 2020;100(17).doi:10.2340/00015555-3653-4
54. Talamonti M, Galluzzo M, Silvaggio D, Lombardo P, Tartaglia C, Bianchi L. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med. 2021;10(6):1298. doi:10.3390/jcm10061298-1
55. Kobusiewicz AK, Tarkowski B, Kaszuba A, Lesiak A, Narbutt J, Zalewska-Janowska A. The relationship between atopic dermatitis and atopic itch in children and the psychosocial functioning of their mothers: A cross-sectional study. Front Med (Lausanne). 2023;10:1066495. doi:10.3389/fmed.2023.1066495-2
56. Shin JO, Kim K, Kim HS, et al. Geographic differences in atopic dermatitis risk between urban and rural area: A systematic review and meta-analysis. J Dtsch Dermatol Ges. 2023;21(9):973-982. doi:10.1111/ddg.15135
57. Bilgic A, Bozca BC, Subası GY, et al. Standard Patch Test Results and Clinical Relevance: A Cross-Sectional Study of 10-year Retrospective Experience. Indian J Dermatol. 2022;67(3):258-264. doi:10.4103/ijd.ijd_965_21. PMID: 36386088; PMCID: PMC9644757.
58. Lefevre MA, Nosbaum A, Mosnier A, et al. Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis. J Am Acad Dermatol. 2024;90(5):953-962. doi:10.1016/j.jaad.2023.11.066
59. World Health Organization (WHO). Immunizing the public against misinformation. Available at: https://www.who.int/news-room/feature-stories/detail/immunizing-the-public-againstmisinformation. Accessed August 20, 2024.
60. O'Connor C, Murphy M. Scratching the surface: a review of online misinformation and conspiracy theories in atopic dermatitis. Clin Exp Dermatol. 2021;46(8):1545-1547. doi:10.1111/ced.14679
61. Mueller S, Hongler V, Jungo P, et al. Fiction, falsehoods, and few facts: cross-sectional study on the content-related quality of atopic eczema-related videos on YouTube. J Med Internet Res. 2020;22(4). doi:10.2196/15599
62. Johnston GA, Bilbao RM, Graham-Brown RA. The use of dietary manipulation by parents of children with atopic dermatitis. Br J Dermatol. 2004;150(6):1186-1189. doi:10.1111/j.1365-2133.2004.05888.x
63. Webber SA, Graham-Brown RA, Hutchinson PE, Burns DA. Dietary manipulation in childhood atopic dermatitis. Br J Dermatol. 1989;121(1):91-98. doi:10.1111/j.1365-2133.1989.tb01404.x
64. Hon KL, Nip SY, Cheung KL. A tragic case of atopic eczema: malnutrition and infections despite multivitamins and supplements. Iran J Allergy Asthma Immunol. 2012;11(3):267-270. PMID:22947914
65. Mori F, Serranti D, Barni S, et al. A kwashiorkor case due to the use of an exclusive rice milk diet to treat atopic dermatitis. Nutr J. 2015;14:83. doi:10.1186/s12937-015-0071-7
66. Tierney EP, Sage RJ, Shwayder T. Kwashiorkor from a severe dietary restriction in an 8-month infant in suburban Detroit, Michigan: case report and review of the literature. Int J Dermatol. 2010;49(5):500-506. doi:10.1111/j.1365-4632.2010.04253.x
67. Patel NU, D’Ambra V, Feldman SR. Increasing Adherence with Topical Agents for Atopic Dermatitis. Am J Clin Dermatol. 2017;18:323-332. doi:10.1007/s40257-017-0261-5.
68. Smith SD, Farrugia LL, Harris V, et al. Evaluation of the Influence of Family and Friends, and the Internet on Patient Perceptions of Long-Term Topical Corticosteroid Use. J Dermatolog Treat. 2017;28(7):642-646. doi:10.1080/09546634.2017.1306017. PMID: 28349719.
69. Dufresne H, Bataille P, Bellon N, et al. Risk Factors for Corticophobia in Atopic Dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12). doi:10.1111/jdv.16739. PMID: 32526095.
70. Kojima R, Fujiwara T, Matsuda A, et al. Factors Associated with Steroid Phobia in Caregivers of Children with Atopic Dermatitis. Pediatr Dermatol. 2013;30(1):29-35. doi:10.1111/j.1525-1470.2012.01808.x. PMID: 22747965.
71. Mueller SM, Tomaschett D, Vogt DR, et al. Topical Corticosteroid Concerns from the Clinicians' Perspective. J Dermatolog Treat. 2017;28(5):464-468. doi:10.1080/09546634.2016.1255307. PMID: 27807999.
72. Choi E, Tan KW, Tang F, Tan C, Chandran NS. Efficacy of Targeted Education in Reducing Topical Steroid Phobia: A Randomized Clinical Trial. J Am Acad Dermatol. 2020;83(6):1681-1687. doi:10.1016/j.jaad.2020.02.079. PMID: 32171815.
73. Smith SD, Stephens AM, Werren JC, Fischer GO. Treatment Failure in Atopic Dermatitis as a Result of Parental Health Belief. Med J Aust. 2013;199(7):467-469. doi:10.5694/mja12.10802. PMID: 24099206.
74. Contento M, Cline A, Russo M. Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions. Am J Clin Dermatol. 2021;22(6):837-851. doi:10.1007/s40257-021-00623-6. PMID: 34287768.
75. Flohr C. How We Treat Atopic Dermatitis Now and How That Will Change Over the Next 5 Years. Br J Dermatol. 2023;188(6):718-725. doi:10.1093/bjd/ljac116. PMID: 36715500.
76. Wilkes SR, Nankervis H, Tavernier E, Maruani A, Williams HC. How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema? J Invest Dermatol. 2016;136(10):1944-1949. doi:10.1016/j.jid.2016.05.104. PMID: 27265005.
77. The Treatment of Severe Atopic Eczema in Children Taskforce. Available at: https://treat-trial.org.uk. Accessed August 25, 2024.
78. Beacon Trial – Best Systemic Treatments for Adults with Atopic Eczema Over the Long Term. Available at: https://beacontrial.org. Accessed August 25, 2024.
79. Cochrane Training. Available at: https://training.cochrane.org/handbook/current/chapter-11. Accessed August 25, 2024.
80. Patel N, Sil A. Dermatology and Randomized Control Trials. Indian Dermatol Online J. 2021;12(3):400-407. doi:10.4103/idoj.IDOJ_715_20. PMID: 34211905; PMCID: PMC8202471.
81. Spelsberg A, Prugger C, Doshi P, et al. Contribution of Industry Funded Post-Marketing Studies to Drug Safety: Survey of Notifications Submitted to Regulatory Agencies. BMJ. 2017;356. doi:10.1136/bmj.j337. PMID: 28174182; PMCID: PMC5477378.
82. Vermeulen FM, Gerbens LAA, Bosma AL, et al. TREatment of ATopic Eczema (TREAT) Registry Taskforce: Consensus on How and When to Measure the Core Dataset for Atopic Eczema Treatment Research Registries. Br J Dermatol. 2019;181(3):492-504. doi:10.1111/bjd.17715. PMID: 30719709; PMCID: PMC6771812.
83. Home for Eczema. Available at: https://www.homeforeczema.org/about/about.aspx. Accessed August 25, 2024.
84. Bieber T. Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease. Nat Rev Drug Discov. 2022;21(1):21-40. doi:10.1038/s41573-021-00266-6. PMID: 34417579; PMCID: PMC8377708.
85. Augustin M, Langenbruch A, Blome C, et al. Characterizing Treatment-Related Patient Needs in Atopic Eczema: Insights for Personalized Goal Orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142-152. doi:10.1111/jdv.15919. Erratum in: J Eur Acad Dermatol Venereol. 2020;34(5):1118. doi:10.1111/jdv.16351. PMID: 31465587.
86. BIOMAP - Biomarkers in Atopic Dermatitis and Psoriasis. Available at: https://www.biomap-imi.eu/overview. Accessed August 25, 2024.
87. Eczema Therapies. Eczema Therapies website. https://eczematherapies.com/. Updated July 17, 2024. Accessed September 26, 2024.
88. Li W, Yosipovitch G. The role of the microbiome and microbiome-derived metabolites in atopic dermatitis and non-histaminergic itch. Am J Clin Dermatol. 2020;21:44-50. doi:10.1007/s40257-019-00495-z.
89. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-859. doi:10.1101/gr.131029.111.
90. De Pessemier B, Grine L, Debaere M, Maes A, Paetzold B, Callewaert C. Gut–Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. Microorganisms. 2021; 9(2):353. https://doi.org/10.3390/microorganisms9020353
91. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-859. doi:10.1101/gr.131029.111
92. Song H, Yoo Y, Hwang J, Na YC, Kim HS. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol. 2016;137(3):852-860. doi:10.1016/j.jaci.2015.08.021
93. Lee E, Lee SY, Kang MJ, Kim K, Won S, Kim BJ, Choi KY, Kim BS, Cho HJ, Kim Y, et al. Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammation. Ann Allergy Asthma Immunol. 2016;117(1):91-92.
94. Kim NY, Ji GE. Effects of probiotics on the prevention of atopic dermatitis. Korean J Pediatr. 2012;55(6):193-201. doi:10.3345/kjp.2012.55.6.193
95. Zhao H, Ma X, Song J, et al. From gut to skin: exploring the potential of natural products targeting microorganisms for atopic dermatitis treatment. Food Funct. 2023;14(17):7825-7852. Published 2023 Aug 29. doi:10.1039/d3fo02455e
96. Anania C, Brindisi G, Martinelli I, et al. Probiotics Function in Preventing Atopic Dermatitis in Children. International Journal of Molecular Sciences. 2022;23(10):5409-5409
97. Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38(2):340-353. doi:10.1111/jdv.19500
98. Augustin M, Misery L, von Kobyletzski L, et al. Systematic literature review assessing the overall costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2022;36(12):2316-2324. doi:10.1111/jdv.18481
99. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. doi:10.1016/j.jid.2016.07.012
100. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. doi:10.1016/j.jid.2016.07.012
101. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol. 2002;46(3):361-370. doi:10.1067/mjd.2002.120528
102. Drucker AM, Wang AR, Qureshi AA. Research gaps in quality of life and economic burden of atopic dermatitis: the National Eczema Association burden of disease audit. JAMA Dermatol. 2016;152(8):873-874. doi:10.1001/jamadermatol.2016.1978
103. Ismail N, Bray N. Atopic dermatitis: economic burden and strategies for high-quality care. Br J Dermatol. 2020;182(5):1087-1088. doi:10.1111/bjd.18636